Novel Approach Simplifies Complex Sugars on Protein-Based Biotech Medicines
By LabMedica International staff writers Posted on 25 May 2014 |
A team of biotech medicine developers has established a cell-based production method that reduces the complexity of the sugars (glycans) expressed on protein-based drugs.
Heterogeneity in the N-glycans on therapeutic proteins causes difficulties for protein purification and process reproducibility and can lead to variable therapeutic efficacy. This heterogeneity arises from the multistep process of mammalian complex-type N-glycan synthesis.
Investigators at, Ghent University (Belgium) recently described a novel glycoengineering strategy that they called GlycoDelete, which used a fungal enzyme to shorten the Golgi N-glycosylation pathway in mammalian cells.
They wrote in the April 20, 2014, online edition of the journal Nature Biotechnology that this shortening resulted in the expression of proteins with small, sialylated trisaccharide N-glycans and reduced complexity compared to native mammalian cell glycoproteins. GlycoDelete engineering did not interfere with the functioning of N-glycans in protein folding, and the physiology of cells modified by GlycoDelete was similar to that of wild-type cells. This strategy for reducing N-glycan heterogeneity on mammalian proteins could lead to more consistent performance of therapeutic proteins and modulation of biopharmaceutical functions.
Senior author Dr. Nico Callewaert, professor of medical biotechnology at Ghent University, said, “This technology has allowed us to solve an old biotech problem. Since the 1990s, nearly everyone has been working to make the sugar synthesis in biotech production cells as similar to human cells as possible. This is a very difficult task, because there are so many steps in this synthesis pathway. We have been able to create a detour in this synthesis pathway in a fairly simple manner, making the pathway much shorter and simpler.”
Related Links:
Ghent University
Heterogeneity in the N-glycans on therapeutic proteins causes difficulties for protein purification and process reproducibility and can lead to variable therapeutic efficacy. This heterogeneity arises from the multistep process of mammalian complex-type N-glycan synthesis.
Investigators at, Ghent University (Belgium) recently described a novel glycoengineering strategy that they called GlycoDelete, which used a fungal enzyme to shorten the Golgi N-glycosylation pathway in mammalian cells.
They wrote in the April 20, 2014, online edition of the journal Nature Biotechnology that this shortening resulted in the expression of proteins with small, sialylated trisaccharide N-glycans and reduced complexity compared to native mammalian cell glycoproteins. GlycoDelete engineering did not interfere with the functioning of N-glycans in protein folding, and the physiology of cells modified by GlycoDelete was similar to that of wild-type cells. This strategy for reducing N-glycan heterogeneity on mammalian proteins could lead to more consistent performance of therapeutic proteins and modulation of biopharmaceutical functions.
Senior author Dr. Nico Callewaert, professor of medical biotechnology at Ghent University, said, “This technology has allowed us to solve an old biotech problem. Since the 1990s, nearly everyone has been working to make the sugar synthesis in biotech production cells as similar to human cells as possible. This is a very difficult task, because there are so many steps in this synthesis pathway. We have been able to create a detour in this synthesis pathway in a fairly simple manner, making the pathway much shorter and simpler.”
Related Links:
Ghent University
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples